IL35986A - Amylase inhibitor,its production and use - Google Patents
Amylase inhibitor,its production and useInfo
- Publication number
- IL35986A IL35986A IL35986A IL3598671A IL35986A IL 35986 A IL35986 A IL 35986A IL 35986 A IL35986 A IL 35986A IL 3598671 A IL3598671 A IL 3598671A IL 35986 A IL35986 A IL 35986A
- Authority
- IL
- Israel
- Prior art keywords
- amylase
- inhibitor
- pancreas
- aqueous
- wheat
- Prior art date
Links
- 229940122816 Amylase inhibitor Drugs 0.000 title claims description 13
- 239000003392 amylase inhibitor Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 25
- 210000000496 pancreas Anatomy 0.000 claims description 22
- 241000209140 Triticum Species 0.000 claims description 18
- 235000021307 Triticum Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 9
- 108010068370 Glutens Proteins 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 235000021312 gluten Nutrition 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 238000000862 absorption spectrum Methods 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 102000057297 Pepsin A Human genes 0.000 claims 1
- 108090000284 Pepsin A Proteins 0.000 claims 1
- 239000008151 electrolyte solution Substances 0.000 claims 1
- 229940021013 electrolyte solution Drugs 0.000 claims 1
- 229940111202 pepsin Drugs 0.000 claims 1
- 102000013142 Amylases Human genes 0.000 description 33
- 108010065511 Amylases Proteins 0.000 description 33
- 235000019418 amylase Nutrition 0.000 description 33
- 239000004382 Amylase Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000013312 flour Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940025131 amylases Drugs 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 229940100445 wheat starch Drugs 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical class O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XLVYRWBZQRKWSI-UHFFFAOYSA-M [Cl-].[Na+].S(=O)(=O)([O-])O.[NH4+] Chemical compound [Cl-].[Na+].S(=O)(=O)([O-])O.[NH4+] XLVYRWBZQRKWSI-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Description
its production and use BAYER A It is known that can be inhibited by various lo substances such as salicylic acid and abiscisine Larsson 861 1665 is known there also exist substances higher molecular weight which are capable of unspecifically inhibiting the activity of some amylases by physical adsorption and 28 296 or by denaturing and precipitation of the enzyme Acta it has been observed that it is possible to elute with distilled from wheat a substance which reduces the dextrifying activity of saliva but has little influence on the activity of pancreas amylase 235 It is a disadvantage of the substances described above that the inhibition of the amylase is either unspecific as our own investigations have inhibiting activity Of the described substances is particularly in relation to pancreas that is to say that almost complete inhibition of the amylases to 0 and are onl achieved with a very high ratio of inhibitor to enzyme this shows the inhibition course of the amylese inhibitor according to the invention in comparison with an inhibitor prepared according to the instructions given by Kneen in relation to amylase units of pancreas am It has now been found that it is possible to extract a highly active inhibitor for pancreas amylase which wheat flour or with the aid of aqueous electrolyte preferably dilute acids alcohol preferably at acid pH values The so obtained inhibits pancreas amylase at a very low ratio to the extent of than 1 The same substance also inhibits saliva amylase to a high Other hydrolases so far as they have been chymotrypsin and ribonuclease are not inhibited by this The inter as starting material is the protein component of wheat and is obtained as a byproduct in the production of wheat starch Handbuch der pharmazeutischen Julius von 1925 page 332 Blish in Advances in Protein New 1 page The new substance is colourless and dissolves readily in dilute acids and alkaline solutions as well as in aqueous The absorption spectrum of a aqueous solution of the inhibitor is shown in The absorption maximum lies at The is insoluble in acetone and absolute The new inhibitor cannot be The substance can with 2 trichloroacetic the precipitate is soluble in H2P and still exhibits 60 to of its initial The substance is slowly inactivated by proteases Solutions of the substance are comparatively stable to acid 1 to 2 but labile to incubation at in pH 1 leads to an loss f Neutral aqueous From inaetivation the amylase inhibitor oecors rapidly increases as the duration of incubation is increased in m g CaCl2 pH By the addition of urea up to a concentration of 2 the inhibitor is not up to it is inactivated to 50 According to the amylase inhibitor is a The inhibiting capacity of the best inhibitor preparations in relation to pig pancreas amylase amounts to 700 to 800 pancreas amylase units per in relation to saliva amylase to 900 to 1000 saliva amylase units per The high activity of this inhibitor also against pancreas amylase curve distinguishes inhibitor from that described by curve which saliva amylase with about half the capacity of 500 saliva but has only a poor activit against pancreas amylases 10 pancreas and can inhibit hardly more than of the pancreas amylase activity even if added in large amounts curve One amylase inhibitor unit is defined as the amount of inhibitor which inhibits one amylase unit to 90 90 inhibition was chosen because of easier tion when determining the inhibition Complete inhibition is achieved asymptotically 1 and One amylase unit is the amount of enzyme which splits 1 μ equivalent of glucosidic bonds in starch within one minute under the stated test The μ gramme equivalent of split bonds are colorimetrically determined with dinitroealicylic acid as μ gramme equivalent of reducing sugars formed and are To carry out the ml amylase solution to 22 are mixed with 0 to inhibitor in 04 of m sodium glycerophosphate buff m pH and equilibrated on a water bath of for about 10 to 20 The mixture is then incubated at for minutes with ml of a starch solutio facturers which been heated to and subsequently mixed with 1 ml of salicylic acid reagent to Bernfeld in page To develop the the mixture is heated on a boiling water bath for 5 is then cooled and 10 ml of distilled water are The extinction at is measured against a blank value prepared the amylase activity which is still effective after addition of the inhibitor is read from a previously plotted amylase curve and the percentage inhibition of the amylase used is calculated The percentage inhibition is plotted as a function of the quotient inhibitor referred to dry substance in the mixture the seriee the 0 inhibition point is read from the curve and recalculated for mg The extraction of the inhibitor according to the invention from wheat shredded wheat or gluten is carried out according to the invention either with 10 to preferabl 30 to 70 mixtures soluble lower alcohols such as propanol preferably dilute aqueous at pH values of to preferably at pH values of 2 to or with alcohol mixtures of the composition stated under but at acid pH values of 1 to 6 preferably 2 to the presence of mineral acids or organic For this part by weight of wheat shredded wheat or gluten is homogenized with 1 to parts by preferably 2 to parts by of the appropriate extraction medium for 1 to 2 minutes and the mixture is subsequently stirred for to hours 1 to 2 at room temperature to The mixture is then filtered or centrifuged at 3000 to 10000 g for 10 to 20 If the residue is reextracted 1 to 2 parts by weight of the extraction as described centrifuged or The supernatant solutions or filtrates are in the case of acidic they are preferably with a concentrated and freed from the ballast proteins precipitated in the course of neutralisation by filtration or In contrast to aqueous wheat flour extracts which are capable of very effectively inhibiting amylases but not pancreas amylases 3 curve the extracts prepared according to the invention by the methods to show an high inhibiting activity also against pancreas amylases curves 3 illustrates the inhibition of pig pancreas amylase by a an acidic aqueous a aqueous ethanolic 3 and an aqueous neutral extract from wheat In each 1 part by weight of wheat flour was extracted with parts b of extraction a ent at for one s amylase inhibitor according to the invention is the extraction of wheat flour or gluten with acidic aqueous alcohols to methanol or pH 2 to This method gives higher yields of inhibitor than the extraction with neutral aqueous alcohols compared with the acidic aqueous extraction mixtures it has the advantage that the mixture is less viscous and therefore easier to for centrifuging the coextraction observed in processes and of an amylase which is present in wheat flour and cannot be inhibited is obviated in this process and inactivation or separation of the vegetable amylase is therefore When gluten is used as starting the yields are 5 to 8 higher with the use of wheat Another advantage consists in that the extraction mixtures are easier to filter and centrifuge and that the amylase inhibitor is obtained with a higher specific activit when gluten is used as starting Isolation of the inhibitor from the extraction solutions are previously neutralised in processes B and can be carried out in various Concentration of the extracts under reduced pressure to 20 mm at temperatures up to to about to of the starting The concentrated extract is filtered or centrifuged and the clear filtrate the clear natant is lyophilized after Precipitation of inhibitors from the extracts with the aid of This process is mainly suitable extracts still having a high content of alcohol concentration above since relatively complete not too high can only be attained from such extracts The precipitation is achieved by pouring 1 part by volume of the solut ion to be precipitated into 2 to parts by volume acetone upon the alcohol content of the extraction solution to be precipitated Drying of the inhibitor preparation in a vacuum at room temperature after washing with absolute alcohol Precipitation of the inhibitors from the extracts or the extracts concentrated according to by the addition of lower alcohols up to a per cent by volume content of 95 for ethanol 90 for or 80 for isopropanol The amylase inhibitor can also be precipitated methanol but in lower yields than are obtained with the use of the aforesaid alcohols Since low alcohol concentrations lead to the precipitation of inactive accompanying substances proteins the precipitation process is also for fractional precipitation out of the amylase inhibitor from the extracts from the extracts concentrated according to e with sodium chloride ammonium sulphate etc Precipitation of the amylase inhibitor from extracts with a certain alcohol content at low temperatures For this purpose the extracts are firet ad justed to alcohol concentrations of 10 to 50 preferably 20 to subsequently kept for several hours to hours at below preferably at to The settle s well and the clear supernatant liquid can be drawn off The remaining precipitate is centrifuged absolute ethanol or about 5 parts volume of absolute preferably in the cold and subsequently dried at room preferably in a This method is also suitable for fractional precipitation different It is known that after the intake of containing food potato alimentary occur in animals and humans this is caused by a rapid decomposition of the amylase and pancreas amylase and according to the following scheme maltase starch maltose glucose or glycogen These hyperglycaemiae are particularly marked and persistent in In adipose persons the alimentary caemia frequently gives rise to a particularly strong of insulin which in turn leads to increased formation of fat and decomposition of It has been found that the amylase according to the isolated by the above significantly reduces alimentary hyperglycaemia six healthy test persons after with wheat starch Experiment Example is therefore suitable as therapeutical agent for diabetes and Doeage to once or several times daily per during Forms of granules kg mouse per os were tolerated without Combinations with the oral sulphonyl derivatives blood depressing biguanides are also of Example 1 1 kg of wheat flour is homogenized 2 litres of pH 3 to to pH to with and stirred at room temperature for 30 The mixture is then centrifuged at 6000 for 10 minutes the supernatant liquid is stored and the residue is reextracted as described above with further 2 litres ethanol at pH 3 to The combined supernatant liquids are with concentrated aiimonia and the flocculated ballast proteins are removed by centrifuging 10 The clear slightly yellowish supernatant liquid litres is trated of its volume at about 20 mm Hg and a bath temperature of to again freed from precipitated proteins by centrifuging and after dialysis distilled water room it is frozen and 10 g with 000 pancreas lyophilisate g inhibitor dry substance with pancreas kg of wheat flour is homogenized wit litres of ethanol in a adjusted to pH 3 to with hydrochloric acid and stirred at room temperature for 60 The is centrifuged at 6000 for 10 the supernatant liquid is adjusted with to pH and centrifuged from the ballast The clear supernatant liquid is stored overnight the precipitated sediment is collected in centrifuging glass vessels at 20 cooling 10 6000 It is mixed with cold absolute ethanol temperature from now with absolute alcohol and dried in a vacuum 10 g with pancreas 8g inhibitor substance with pancreas Example 200 g of flour are homogenized with 800 ml of adjusted with HCl to pH and stirred at room temperature for 30 The mixture is subsequently centrifuged for 30 minutes at the turbid supernatant liquid is neutralised with and again centrifuged at 30 The 600 ml of turbid supernatant liquid are mixed with 1100 ml of absolute filtered and the inhibitor is precipitated from the filtrate with a further 5 litres of absolute It is washed with absolute ethanol and dried in a 1 g with pancreas if 500 g of wheat flour are homogenized with 2 litres of 7 methanol for 2 stirred at room temperature for 1 and subsequently filtered through two large fluted The clear filtrate is added dropwise with stirring to parts by volume The inhibitor settles at the bottom in the form of thick white The clear supernatant liquid is decanted and the white sediment is taken Up in absolute washed and finally dried at room Example 5 The antihyperglycaemic effect of the amylase hibitor was tested the following test arrangement 100 g of cereal starch were administered in the of an aqueous suspension os to 6 healthy test The blood sugar was determined immediately before the start of the test and at short intervals until 3 hours tion of the starch by means of the to 51 In two further the amylase inhibitor taken up in slime was applied in the same test arrangement to the same six test persons per os immediately before application the Example 6 kg gluten manufacturers Crespel and were introduced in portions with intense stirring into litres of The mixture was then with hydrochloric acid to the viscosity of solution increased The mixture was stirred fqr minutes and subsequently neutralised with Flocculation The mixture was centrifuged for 10 minutes at about 2000 and the clear centrifugate was cooled to The precipitate flocculating in the cold settled well over The supernatant clear solution was the sediment collected in a cooling centrifuge at after washing with alcohol and dried in a vacuum at room 180 g pancreas Table re Example 5 Change of blood glucose as of initia of six healthy test persons value 1 at different times after oral administration of wheat starch after previous application of the amylase as against control test as against control test as against control test insufficientOCRQuality
Claims (1)
1. CLAIMS Amylase inhibitor derived from being a colorless readily soluble in dilute alkaline solutions and aqueous alcohol and insoluble in absolute having high activity against pancreas and saliva while being inactive against pepsin and ribonuclease and having the absorption spectrum of a aqueous solution as shown in Figure 2 of the accompanying Amylase inhibitor according Claim being obtained from k process for the production of an inhibitor according to 1 or characterised in that wheat shredded wheat or gluten is extracted with alcohol or with aqueous 3 electrolyte solutions at pH values of 1 to and the amylase inhibitor is isolated from the For the Applicants AND PARTNERS insufficientOCRQuality
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2003934A DE2003934C3 (en) | 1970-01-29 | 1970-01-29 | Amylase inhibitor |
DE2028739A DE2028739C3 (en) | 1970-06-11 | 1970-06-11 | Amylase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
IL35986A0 IL35986A0 (en) | 1971-03-24 |
IL35986A true IL35986A (en) | 1974-10-22 |
Family
ID=25758557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL35986A IL35986A (en) | 1970-01-29 | 1971-01-12 | Amylase inhibitor,its production and use |
Country Status (13)
Country | Link |
---|---|
AT (1) | AT303253B (en) |
BE (1) | BE762265A (en) |
CA (1) | CA946838A (en) |
CH (1) | CH559215A5 (en) |
CS (1) | CS156486B2 (en) |
DK (1) | DK127166B (en) |
ES (1) | ES387656A1 (en) |
FI (1) | FI49309C (en) |
FR (1) | FR2081468B1 (en) |
GB (1) | GB1330230A (en) |
IE (1) | IE34869B1 (en) |
IL (1) | IL35986A (en) |
NL (1) | NL7101078A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2701890C2 (en) | 1977-01-19 | 1983-08-04 | Hoechst Ag, 6230 Frankfurt | Streptomycete peptic glycoside hydrolase inhibitor and its use |
US4910297A (en) * | 1987-06-29 | 1990-03-20 | Abi Biotechnology Inc. | Alpha-amylase inhibitor |
JP2757405B2 (en) * | 1988-12-09 | 1998-05-25 | 日清製粉株式会社 | Diet preparation containing α-amylase inhibitor obtained from wheat |
US6858234B2 (en) * | 2002-01-25 | 2005-02-22 | Nisshin Pharma Inc. | Process for the preparation of amylase inhibitor |
CN108576735B (en) * | 2018-05-09 | 2022-03-15 | 北京市农林科学院 | Jelly with effect of inhibiting starch decomposition and preparation method thereof |
-
1971
- 1971-01-12 IL IL35986A patent/IL35986A/en unknown
- 1971-01-12 IE IE30/71A patent/IE34869B1/en unknown
- 1971-01-14 AT AT27171A patent/AT303253B/en not_active IP Right Cessation
- 1971-01-21 FI FI710163A patent/FI49309C/en active
- 1971-01-25 CA CA103,510A patent/CA946838A/en not_active Expired
- 1971-01-27 ES ES387656A patent/ES387656A1/en not_active Expired
- 1971-01-27 NL NL7101078A patent/NL7101078A/xx unknown
- 1971-01-28 CS CS62271*#A patent/CS156486B2/cs unknown
- 1971-01-28 DK DK37471AA patent/DK127166B/en unknown
- 1971-01-29 CH CH136971A patent/CH559215A5/xx not_active IP Right Cessation
- 1971-01-29 FR FR7103140A patent/FR2081468B1/fr not_active Expired
- 1971-01-29 BE BE762265A patent/BE762265A/xx unknown
- 1971-04-19 GB GB2058171A patent/GB1330230A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CH559215A5 (en) | 1975-02-28 |
FI49309C (en) | 1975-05-12 |
CS156486B2 (en) | 1974-07-24 |
FR2081468A1 (en) | 1971-12-03 |
DK127166B (en) | 1973-10-01 |
CA946838A (en) | 1974-05-07 |
ES387656A1 (en) | 1974-02-16 |
NL7101078A (en) | 1971-08-02 |
FI49309B (en) | 1975-01-31 |
IL35986A0 (en) | 1971-03-24 |
BE762265A (en) | 1971-07-29 |
FR2081468B1 (en) | 1974-08-23 |
GB1330230A (en) | 1973-09-12 |
AT303253B (en) | 1972-11-27 |
IE34869B1 (en) | 1975-09-03 |
IE34869L (en) | 1971-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3950319A (en) | Amylase inhibitor from wheat gluten using alcohol | |
Horio et al. | Preparation of crystalline Pseudomonas cytochrome c-551 and its general properties | |
Lyman et al. | Reactions of proteins with gossypol | |
AU666531B2 (en) | Processes for the preparation of amylase inhibitor | |
US5332503A (en) | Process for purifying collagenase | |
IL35986A (en) | Amylase inhibitor,its production and use | |
Platt et al. | The estimation of inositol in animal tissues | |
Pollock et al. | Enzymes of barley and malt III. The latent β‐amylase of barley | |
Heppel | [80] Intestinal phosphomonoesterase | |
Grossberg et al. | Proteins of Canine Gastric Juice Electrophoretic Characterization and Separation of Fractions | |
US2488564A (en) | Preparation of hyaluronidase | |
FUKUSHIMA | Studies on Soybean Proteins Part II. A New Method for Quantitative Determination of the Degree of Denaturation of Protein in Soybean Flour | |
Ito et al. | Milk fat globule membrane substances inhibit mouse intestinal β‐glucuronidase | |
US3823072A (en) | Analysis of proteolytic enzymes | |
US3267006A (en) | Pancreatic collagenase and preparation of same | |
Hayashi et al. | Yeast Pro-proteinase C Part II. Isolation and Some Physicochemical Properties | |
Spies et al. | The Chemistry of Allergens. VI. Chemical Composition and Properties of an Active Carbohydrate-free Protein from Cottonseed*, 1 | |
US3925158A (en) | Process of manufacturing enzyme preparation rich in lipase | |
SU535912A3 (en) | Method of producing orgotein | |
US2922745A (en) | Purification of profibrinolysin | |
US2794800A (en) | Preparation of antitryptic substance from soybean | |
Green et al. | Coenzyme factor of yeast | |
Asato et al. | Fractionation and isolation of the multiple forms of prorennin (prochymosin) | |
Sherman et al. | EXPERIMENTS UPON THE AMYLASE OF ASPERGILLUS ORYZAE. | |
US4410531A (en) | Enzyme derived from hyaluronidase |